Back to results

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC)

Primary Purpose

Breast Neoplasms

Status

Active

Phase

Phase 1

Locations

International

Study Type

Interventional

Intervention

Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

Bevacizumab

Entinostat

Exemestane

Fulvestrant

Ipatasertib

Tamoxifen

Abemaciclib

About this trial

This is an interventional treatment trial for Breast Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria for Both Stages:

Measurable disease per RECIST v1.1
Adequate hematologic and end organ function
Disease progression during or after first- or second-line hormonal therapy with CDK4/6 inhibitor

Inclusion Criteria for Stage 1:

Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Metastatic or inoperable, locally advanced, histologically or cytologically confirmed invasive HR-positive HER2-negative breast cancer
Recommended for endocrine therapy, and cytotoxic chemotherapy not indicated at study entry
Recurrence or progression following most recent systemic breast cancer therapy
Disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease
Postmenopausal according to protocol-defined criteria
Life expectancy >3 months
Available tumor specimen for determination of PD-L1 status

Inclusion Criteria for Stage 2:

ECOG performance status of 0-2
Ability to initiate treatment within 3 months after disease progression or unacceptable toxicity on a Stage 1 regimen

Exclusion Criteria for Both Stages:

Significant or uncontrolled comorbid disease as specified in the protocol
Uncontrolled tumor-related pain
Autoimmune disease except for stable/controlled hypothyroidism, Type 1 diabetes mellitus, or certain dermatologic conditions
Positive human immunodeficiency virus test
Active hepatitis B or C
Active tuberculosis
Severe infection within 4 weeks and/or antibiotics within 2 weeks prior to study treatment
Prior allogeneic stem cell or solid organ transplantation
History of malignancy other than breast cancer within 2 years prior to screening except those with negligible risk of metastasis/death
History of or known hypersensitivity to study drug or excipients
For patients entering Stage 2, recovery from all immunotherapy-related adverse events to Grade 1 or better or to baseline at the time of consent

Exclusion Criteria for Stage 1:

Prior fulvestrant or cytotoxic chemotherapy for metastatic breast cancer, or certain other agents as specified in the protocol
Unresolved AEs from prior anti-cancer therapy
Eligibility only for the control arm
Prior treatment with inhibitors as specified in the protocol

Exclusion Criteria for Stage 2:

Unacceptable toxicity with atezolizumab during Stage 1
Uncontrolled cardiovascular disease or coagulation disorder, including use of anticoagulants as specified in the protocol
Significant abdominal or intestinal manifestations within 6 months prior to treatment
Grade 2 or higher proteinuria

Sites / Locations

University of Alabama at Birmingham
Cedars-Sinai Medical Center
UCSF Helen Diller Family CCC
Stanford Cancer Institute
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Wellness Oncology and Hematology - Main Office
Northwest Georgia Oncology Centers PC - Marietta
Rush University Medical Center - Chicago
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Levine Cancer Institute
The Ohio State University Comprehensive Cancer Center
Providence Cancer Center
UPMC Pinnacle Health System
Thomas Jefferson University Hospital
Univ of Pittsburgh Sch of Med; Magee-Womens Hospital
Sarah Cannon Research Institute
Houston Methodist Hospital; Department of Pharmacy
Northwest Medical Specialties, PLLC; Research Department
Rambam Medical Center
Shaare Zedek Medical Center
Rabin Medical Center-Beilinson Campus; Davidof Institute
Sheba Medical Center
Tel Aviv Sourasky Medical Center; Pharmacy
National Cancer Center
Seoul National University Hospital
University of Ulsan College of Medicine - Asan Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Active Comparator

Experimental

Arm Label

Stage 1: Fulvestrant

Stage 1: Atezolizumab + Entinostat

Stage 1: Atezolizumab + Fulvestrant

Stage 1: Atezolizumab + Ipatasertib

Stage 1: Atezolizumab + Ipatasertib + Fulvestrant

Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy

Stage 1: Mandatory On-Treatment Biopsy

Stage 1: Atezolizumab + Abemaciclib + Fulvestrant

Arm Description

Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.

Participants will receive doublet combination treatment with atezolizumab plus entinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.

Participants will receive triplet combination treatment with atezolizumab plus ipatasertib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.

Those who progress or experience unacceptable toxicity during treatment in Stage 1 may be eligible to enter Stage 2. Participants will receive triplet combination therapy with atezolizumab plus bevacizumab plus one of three endocrine therapies (fulvestrant, exemestane, or tamoxifen) selected by the physician. Treatment in Stage 2 will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

For experimental combination arms that demonstrate clinical activity during the preliminary phase, the Sponsor may open enrollment into a separate mandatory on-treatment biopsy cohort for that combination.

Participants will receive triplet combination treatment with atezolizumab plus abemaciclib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Outcomes

Primary Outcome Measures

Percentage of Participants with Objective Response during Stage 1 According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

Secondary Outcome Measures

Progression-Free Survival during Stage 1 According to RECIST v1.1

Percentage of Participants with Clinical Benefit during Stage 1 According to RECIST v1.1

Overall Survival during Stage 1

Percentage of Participants Alive at 18 Months during Stage 1

Duration of Response during Stage 1 According to RECIST v1.1

Percentage of Participants with Adverse Events (AEs) during Stage 1

Percentage of Participants with AEs during Stage 2

Atezolizumab Serum Concentration during Stage 1

Entinostat Serum and Plasma Concentration during Stage 1

Fulvestrant Plasma Concentration during Stage 1

Ipatasertib Plasma Concentration during Stage 1

Atezolizumab Serum Concentration during Stage 2

Bevacizumab Serum Concentration during Stage 2

Exemestane Plasma Concentration during Stage 2

Fulvestrant Plasma Concentration during Stage 2

Tamoxifen Plasma Concentration during Stage 2

Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab during Stage 1

Percentage of Participants with ADAs to Atezolizumab during Stage 2

Percentage of Participants with ADAs to Bevacizumab during Stage 2

Abemaciclib Plasma Concentration during Stage 1

Full Information

NCT ID

NCT03280563

First Posted

September 11, 2017

Last Updated

September 14, 2023

Sponsor

Hoffmann-La Roche

1. Study Identification

Unique Protocol Identification Number

NCT03280563

Brief Title

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Acronym

MORPHEUS HR+BC

Official Title

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)

Study Type

Interventional

2. Study Status

Record Verification Date

September 2023

Overall Recruitment Status

Active, not recruiting

Study Start Date

December 26, 2017 (Actual)

Primary Completion Date

December 31, 2024 (Anticipated)

Study Completion Date

December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

5. Study Description

Brief Summary

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed during or following treatment with a cyclin-dependent kinase (CDK) 4/6 inhibitor in the first- or second-line setting, such as palbociclib, ribociclib, or abemaciclib. The study will be performed in two stages. During Stage 1, participants will be randomized to fulvestrant (control) or an atezolizumab-containing doublet or triplet combination. Those who experience disease progression, loss of clinical benefit, or unacceptable toxicity may be eligible to receive a new triplet combination treatment in Stage 2 until loss of clinical benefit or unacceptable toxicity. New treatment arms may be added and/or existing treatment arms may be closed during the course of the study on the basis of ongoing clinical efficacy and safety as well as the current treatments available.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Breast Neoplasms

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1, Phase 2

Interventional Study Model

Sequential Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

138 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Stage 1: Fulvestrant

Arm Type

Active Comparator

Arm Description

Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.

Arm Title

Stage 1: Atezolizumab + Entinostat

Arm Type

Experimental

Arm Description

Participants will receive doublet combination treatment with atezolizumab plus entinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Arm Title

Stage 1: Atezolizumab + Fulvestrant

Arm Type

Experimental

Arm Description

Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Arm Title

Stage 1: Atezolizumab + Ipatasertib

Arm Type

Experimental

Arm Description

Arm Title

Stage 1: Atezolizumab + Ipatasertib + Fulvestrant

Arm Type

Experimental

Arm Description

Arm Title

Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy

Arm Type

Experimental

Arm Description

Arm Title

Stage 1: Mandatory On-Treatment Biopsy

Arm Type

Experimental

Arm Description

Arm Title

Stage 1: Atezolizumab + Abemaciclib + Fulvestrant

Arm Type

Experimental

Arm Description

Participants will receive triplet combination treatment with atezolizumab plus abemaciclib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Intervention Type

Drug

Intervention Name(s)

Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

Other Intervention Name(s)

Tecentriq

Intervention Description

Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.

Intervention Type

Drug

Intervention Name(s)

Bevacizumab

Other Intervention Name(s)

Avastin

Intervention Description

Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.

Intervention Type

Drug

Intervention Name(s)

Entinostat

Intervention Description

Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.

Intervention Type

Drug

Intervention Name(s)

Exemestane

Intervention Description

Exemestane will be given as 25 mg orally QD in each 21-day cycle.

Intervention Type

Drug

Intervention Name(s)

Fulvestrant

Intervention Description

Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.

Intervention Type

Drug

Intervention Name(s)

Ipatasertib

Intervention Description

Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.

Intervention Type

Drug

Intervention Name(s)

Tamoxifen

Intervention Description

Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.

Intervention Type

Drug

Intervention Name(s)

Abemaciclib

Intervention Description

Abemaciclib will be given as 150mg twice daily during each 28-day cycle.

Primary Outcome Measure Information:

Title

Percentage of Participants with Objective Response during Stage 1 According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

Time Frame

From baseline until disease progression or loss of clinical benefit (up to 6 years overall)

Secondary Outcome Measure Information:

Title

Progression-Free Survival during Stage 1 According to RECIST v1.1

Time Frame

From randomization until disease progression or death from any cause (up to 6 years overall)

Title

Percentage of Participants with Clinical Benefit during Stage 1 According to RECIST v1.1

Time Frame

From baseline until disease progression or loss of clinical benefit (up to 6 years overall)

Title

Overall Survival during Stage 1

Time Frame

From randomization until death from any cause (up to 6 years overall)

Title

Percentage of Participants Alive at 18 Months during Stage 1

Time Frame

18 months

Title

Duration of Response during Stage 1 According to RECIST v1.1

Time Frame

From first objective response until disease progression or death from any cause (up to 6 years overall)

Title

Percentage of Participants with Adverse Events (AEs) during Stage 1

Time Frame

From baseline until 30 days after last dose or initiation of new systemic anti-cancer therapy (up to 6 years overall)

Title

Percentage of Participants with AEs during Stage 2

Time Frame

From baseline until 30 days after last dose or initiation of new systemic anti-cancer therapy (up to 6 years overall)

Title

Atezolizumab Serum Concentration during Stage 1

Time Frame

Predose (0 hours [h]) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (cycle = 21-28 days); postdose (30 min) (infusion = 30-60 min) on Day 1 of Cycle 1; at treatment discontinuation (up to 6 years); and 120 days after last dose (up to 6 years overall)

Title

Entinostat Serum and Plasma Concentration during Stage 1

Time Frame

Serum predose (0 h) and plasma postdose (2-4 h) on Day 1 of Cycle 1; plasma predose (0 h) on Day 1 of Cycle 2 (cycle = 21 days)

Title

Fulvestrant Plasma Concentration during Stage 1

Time Frame

Predose (0 h) on Day 1 of Cycles 2-3 (cycle = 28 days)

Title

Ipatasertib Plasma Concentration during Stage 1

Time Frame

Predose (0 h) and postdose (1, 2, 4, 6 h) on Day 15 of Cycle 1; postdose (1-3 h) on Day 15 of Cycle 3

Title

Atezolizumab Serum Concentration during Stage 2

Time Frame

Predose (0 h) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (cycle = 21-28 days); postdose (30 min) (infusion = 30-60 min) on Day 1 of Cycle 1; at treatment discontinuation (up to 6 years); and 120 days after last dose (up to 6 years overall)

Title

Bevacizumab Serum Concentration during Stage 2

Time Frame

Predose (0 h) and postdose (30 min) (infusion = 30-90 min) on Day 1 of Cycles 1, 3 (cycle = 21-28 days); at treatment discontinuation (up to 6 years); and 120 days after last dose (up to 6 years overall)

Title

Exemestane Plasma Concentration during Stage 2

Time Frame

Predose (0 h) on Day 1 of Cycle 2 (cycle = 21 days)

Title

Fulvestrant Plasma Concentration during Stage 2

Time Frame

Predose (0 h) on Day 1 of Cycles 2-3 (cycle = 28 days)

Title

Tamoxifen Plasma Concentration during Stage 2

Time Frame

Predose (0 h) on Day 1 of Cycle 2 (cycle = 21 days)

Title

Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab during Stage 1

Time Frame

Predose (0 h) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (cycle = 28 days); at treatment discontinuation (up to 6 years); and 120 days after last dose (up to 6 years overall)

Title

Percentage of Participants with ADAs to Atezolizumab during Stage 2

Time Frame

Predose (0 h) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (cycle = 21-28 days); at treatment discontinuation (up to 6 years); and 120 days after last dose (up to 6 years overall)

Title

Percentage of Participants with ADAs to Bevacizumab during Stage 2

Time Frame

Predose (0 h) on Day 1 of Cycles 1, 3 (cycle = 21-28 days); at treatment discontinuation (up to 6 years); and 120 days after last dose (up to 6 years overall)

Title

Abemaciclib Plasma Concentration during Stage 1

Time Frame

Predose (0 h), Postdose (30 minutes post infusion), and 4-8 hours after dose on Day 1 Cycle 1; Predose on Day 15 Cycle 1 and Day 1 of Cycles 2 and 3

10. Eligibility

Sex

Female

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria for Both Stages: Measurable disease per RECIST v1.1 Adequate hematologic and end organ function Disease progression during or after first- or second-line hormonal therapy with CDK4/6 inhibitor Inclusion Criteria for Stage 1: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Metastatic or inoperable, locally advanced, histologically or cytologically confirmed invasive HR-positive HER2-negative breast cancer Recommended for endocrine therapy, and cytotoxic chemotherapy not indicated at study entry Recurrence or progression following most recent systemic breast cancer therapy Disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease Postmenopausal according to protocol-defined criteria Life expectancy >3 months Available tumor specimen for determination of PD-L1 status Inclusion Criteria for Stage 2: ECOG performance status of 0-2 Ability to initiate treatment within 3 months after disease progression or unacceptable toxicity on a Stage 1 regimen Exclusion Criteria for Both Stages: Significant or uncontrolled comorbid disease as specified in the protocol Uncontrolled tumor-related pain Autoimmune disease except for stable/controlled hypothyroidism, Type 1 diabetes mellitus, or certain dermatologic conditions Positive human immunodeficiency virus test Active hepatitis B or C Active tuberculosis Severe infection within 4 weeks and/or antibiotics within 2 weeks prior to study treatment Prior allogeneic stem cell or solid organ transplantation History of malignancy other than breast cancer within 2 years prior to screening except those with negligible risk of metastasis/death History of or known hypersensitivity to study drug or excipients For patients entering Stage 2, recovery from all immunotherapy-related adverse events to Grade 1 or better or to baseline at the time of consent Exclusion Criteria for Stage 1: Prior fulvestrant or cytotoxic chemotherapy for metastatic breast cancer, or certain other agents as specified in the protocol Unresolved AEs from prior anti-cancer therapy Eligibility only for the control arm Prior treatment with inhibitors as specified in the protocol Exclusion Criteria for Stage 2: Unacceptable toxicity with atezolizumab during Stage 1 Uncontrolled cardiovascular disease or coagulation disorder, including use of anticoagulants as specified in the protocol Significant abdominal or intestinal manifestations within 6 months prior to treatment Grade 2 or higher proteinuria

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Clinical Trials

Organizational Affiliation

Hoffmann-La Roche

Official's Role

Study Director

Facility Information:

Facility Name

University of Alabama at Birmingham

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35249

Country

United States

Facility Name

Cedars-Sinai Medical Center

City

Los Angeles

State/Province

California

ZIP/Postal Code

90048

Country

United States

Facility Name

UCSF Helen Diller Family CCC

City

San Francisco

State/Province

California

ZIP/Postal Code

94158

Country

United States

Facility Name

Stanford Cancer Institute

City

Stanford

State/Province

California

ZIP/Postal Code

94305

Country

United States

Facility Name

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

City

Torrance

State/Province

California

ZIP/Postal Code

90502

Country

United States

Facility Name

Wellness Oncology and Hematology - Main Office

City

West Hills

State/Province

California

ZIP/Postal Code

91307

Country

United States

Facility Name

Northwest Georgia Oncology Centers PC - Marietta

City

Marietta

State/Province

Georgia

ZIP/Postal Code

30060

Country

United States

Facility Name

Rush University Medical Center - Chicago

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60612

Country

United States

Facility Name

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21287

Country

United States

Facility Name

Memorial Sloan Kettering Cancer Center

City

New York

State/Province

New York

ZIP/Postal Code

10065

Country

United States

Facility Name

Levine Cancer Institute

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28204

Country

United States

Facility Name

The Ohio State University Comprehensive Cancer Center

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43221

Country

United States

Facility Name

Providence Cancer Center

City

Portland

State/Province

Oregon

ZIP/Postal Code

97231

Country

United States

Facility Name

UPMC Pinnacle Health System

City

Harrisburg

State/Province

Pennsylvania

ZIP/Postal Code

17102

Country

United States

Facility Name

Thomas Jefferson University Hospital

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Facility Name

Univ of Pittsburgh Sch of Med; Magee-Womens Hospital

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15213

Country

United States

Facility Name

Sarah Cannon Research Institute

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37203

Country

United States

Facility Name

Houston Methodist Hospital; Department of Pharmacy

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

Northwest Medical Specialties, PLLC; Research Department

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

Rambam Medical Center

City

Haifa

ZIP/Postal Code

3109601

Country

Israel

Facility Name

Shaare Zedek Medical Center

City

Jerusalem

ZIP/Postal Code

9103102

Country

Israel

Facility Name

Rabin Medical Center-Beilinson Campus; Davidof Institute

City

Petach Tikva

ZIP/Postal Code

4941492

Country

Israel

Facility Name

Sheba Medical Center

City

Ramat Gan

ZIP/Postal Code

5262100

Country

Israel

Facility Name

Tel Aviv Sourasky Medical Center; Pharmacy

City

Tel Aviv

ZIP/Postal Code

6423906

Country

Israel

Facility Name

National Cancer Center

City

Goyang-si

ZIP/Postal Code

10408

Country

Korea, Republic of

Facility Name

Seoul National University Hospital

City

Seoul

ZIP/Postal Code

03080

Country

Korea, Republic of

Facility Name

University of Ulsan College of Medicine - Asan Medical Center

City

Seoul

ZIP/Postal Code

05505

Country

Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

We'll reach out to this number within 24 hrs